8-K: Apogee Therapeutics Unveils Landmark Phase 2 APEX Trial Results for APG777 in Atopic Dermatitis, Exceeding Efficacy Benchmarks

Apogee Therapeutics announced positive 16-week data from Part A of its Phase 2 APEX clinical trial for APG777 in moderate-to-severe atopic dermatitis, demonstrating superior efficacy and a favorable safety profile compared to existing biologics.

Summary

• Positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 in moderate-to-severe atopic dermatitis (AD) were announced.
• APG777 met its primary endpoint, showing a significantly greater least squares mean percent change from baseline at Week 16 with an Eczema Area Severity Index (EASI) reduction of 71.0% compared to placebo's 33.8% (p < 0.001).
• Achieved the highest absolute and placebo-adjusted EASI-75 of any biologic, with 66.9% of participants treated with APG777 achieving EASI-75 compared to 24.6% on placebo (p < 0.001).
• An exposure-response relationship was observed, with patients in the two highest quartiles of exposures achieving the highest EASI-75 response at Week 16, 83.3% for quartile three and 89.5% for quartile four.
• Treatment with APG777 led to rapid onset of itch relief, achieving a statistically significant reduction by Week 1, with a 50.7% reduction of Itch Numeric Rating Scale (NRS) from baseline compared to 23.2% for placebo (p < 0.01).
• APG777 was well tolerated with a safety profile consistent with its class; serious treatment-emergent adverse events (TEAEs) were rare for APG777-exposed patients (1.2% vs. 2.4% in placebo), and the discontinuation rate due to AEs was low (2.4%).
• The first patient has been dosed in the Phase 1b head-to-head trial of APG279 (IL-13 + OX40L) in patients with moderate-to-severe AD, in comparison to DUPIXENT, with readout expected in the second half of 2026.
• APEX Part B, which is testing a higher dose of APG777, continues to enroll participants with a 16-week readout expected in mid-2026.
• Data readout from the maintenance phase of APEX Part A, testing 3and 6-month maintenance dosing, is expected in the first half of 2026.

Sentiment

Score: 9

Explanation: The document reports overwhelmingly positive Phase 2 clinical trial results for APG777, demonstrating superior efficacy compared to existing biologics and a favorable safety profile. It also highlights a significantly reduced dosing burden and strong future development plans, including a head-to-head trial against a market leader and accelerated timelines for further data readouts. The company also has a strong cash position.

Positives

• APG777 met its primary endpoint, showing a significantly greater EASI reduction of 71.0% compared to placebo's 33.8% (p < 0.001).
• Achieved the highest absolute and placebo-adjusted EASI-75 (66.9% vs. 24.6% placebo, p < 0.001) of any biologic in a global study.
• Observed an exposure-response relationship, with higher exposures leading to higher EASI-75 responses (83.3% for quartile three, 89.5% for quartile four).
• Rapid onset of itch relief, with a 50.7% reduction in Itch NRS from baseline by Week 1 (p < 0.01).
• Favorable safety profile consistent with its class, with low rates of serious TEAEs (1.2%) and discontinuations due to AEs (2.4%).
• No injection site reactions were observed in the APG777 group.
• APG777 Part A induction regimen requires approximately 50% fewer injections and dosing days compared to DUPIXENT or EBGLYSS.
• Potential for best-in-class quarterly or better maintenance dosing (every 3-6 months) compared to existing therapies (every 2-4 weeks).
• Historical correlation data increases confidence that Phase 2 results will translate to Phase 3, with Phase 3 trials for biologics and small molecules in AD having a 100% historical success rate.
• The company has $681M in cash, cash equivalents, marketable securities, and long-term marketable securities as of March 31, 2025, providing a cash runway into Q1 2028.

Risks

• Global macroeconomic conditions and related volatility.
• Expectations regarding the initiation, progress, and expected results of preclinical studies, clinical trials, and research and development programs.
• Expectations regarding the timing, completion, and outcome of clinical trials.
• The unpredictable relationship between preclinical study results and clinical trial results, including across different phases of clinical trials.
• The accuracy of cross-trial comparisons against products in the same class.
• The timing or likelihood of regulatory filings and approvals.
• Liquidity and capital resources.
• Other risks and uncertainties identified in Apogee's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, and subsequent disclosure documents.

Future Outlook

Apogee plans to initiate a Phase 3 trial for APG777 in AD in 2026, with an anticipated commercial launch this decade. The company expects 52-week maintenance data from Part A of the APEX trial in the first half of 2026 and initial readout from Part B in mid-2026. The Phase 1b head-to-head trial of APG279 against DUPIXENT is expected to readout in the second half of 2026. APEX Part B is testing a higher dose of APG777, projected to achieve average exposures in line with the highest quartile of exposures from Part A, aiming for even higher efficacy. Additionally, Apogee plans to initiate a Phase 2b trial for APG777 in asthma in 2025 and a Phase 2 trial in Eosinophilic Esophagitis (EoE) in 2026.

Management Comments

• "APG777 has the potential to set a new standard of care by offering improved clinical responses with transformational quarterly or better maintenance dosing – benefitting patients, providers, and payers. Today’s results bring us closer to that vision, and we believe further de-risks APG777’s path to approval." Michael Henderson, M.D., Chief Executive Officer.
• "In addition to these potentially best-in-class results, increased response rates were observed in patients with higher exposures, supporting our exposure-response hypothesis which we continue to further test in APEX Part B. Combined with a favorable safety profile, these findings reinforce APG777’s potential to deliver meaningful and durable benefit to patients while significantly reducing dosing frequency compared with existing agents." Carl Dambkowski, M.D., Chief Medical Officer.
• "Despite meaningful advances in atopic dermatitis treatment, there remains a significant unmet need to reduce the injection burden for patients while continuing to improve patient outcomes. I look forward to seeing the first half-life extended antibody in AD progress and I am excited about Apogee’s studies that are bringing this therapy closer to patients." Emma Guttman-Yassky, M.D., Ph.D., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai.

Industry Context

The announcement positions Apogee Therapeutics as a strong contender in the inflammatory and immunology (I&I) markets, particularly for atopic dermatitis (AD), which is described as the largest and one of the least penetrated I&I markets. APG777's potential for quarterly or better maintenance dosing aims to address a significant unmet need for reduced injection burden, potentially disrupting the market dominated by therapies requiring more frequent injections. The company is also pursuing combination approaches to potentially exceed monotherapy efficacy ceilings, indicating a strategic move towards comprehensive market leadership in I&I.

Comparison to Industry Standards

• APG777 demonstrated the highest EASI-75 (66.9% absolute, 42.5% placebo-adjusted) of any biologic tested in a global placebo-controlled trial for moderate-to-severe atopic dermatitis at Week 16.
• This compares favorably to DUPIXENT (average of Ph3 SOLO-1&2 and Ph2b; 53.0% EASI-75 absolute, 37.7% placebo-adjusted), EBGLYSS (average of Ph3 ADVOCATE-1&2 and Ph2b; 49.5% EASI-75 absolute, 37.7% placebo-adjusted), ADBRY (average of Ph3 ECZTRA1&2; 29.1% EASI-75 absolute, 17.0% placebo-adjusted), Amlitelimab (Ph2b; 40.3% EASI-75 absolute, 28.9% placebo-adjusted), and Rocatinlimab (Ph3 ROCKET Horizon; 32.8% EASI-75 absolute, 19.1% placebo-adjusted).
• APG777's induction regimen requires approximately 50% fewer injections and dosing days (6 injections, 4 dosing days) compared to DUPIXENT (10 injections, 9 dosing days) or EBGLYSS (11 injections, 9 dosing days).
• APG777 aims for 2-4 annual injections in maintenance, significantly less frequent than EBGLYSS (13-26 injections annually) or DUPIXENT (26 injections annually).
• Key secondary endpoints (vIGA 0/1 of 34.9% vs. 17.3% placebo, p < 0.05; EASI-90 of 33.9% vs. 14.7% placebo, p < 0.05) were in line with standard of care.
• The safety profile of APG777 was consistent with other agents in its class, with a total conjunctivitis rate of 18.3%, similar to DUPIXENT (~5-26%) and EBGLYSS (~3-27%).

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical trial results, potential for a best-in-class product, accelerated development timelines, and a strong cash runway, which could lead to increased share price and long-term value.
• Patients (moderate-to-severe AD): Significant positive impact due to potentially superior efficacy, rapid itch relief, and a substantially reduced injection burden (quarterly or better dosing) compared to current treatments.
• Healthcare Providers: Positive impact by offering a new, highly effective treatment option with a more convenient dosing regimen for patients.
• Payers: Positive impact due to the potential for a more efficient and effective treatment, potentially leading to better patient outcomes and adherence, though cost-effectiveness will be a future consideration.

Next Steps

• Host a conference call and webcast on July 7, 2025, to discuss the data results.
• Continue enrollment for APEX Part B.
• Expect 16-week readout from APEX Part B in mid-2026.
• Expect data readout from the maintenance phase of APEX Part A (3and 6-month dosing) in the first half of 2026.
• Initiate a Phase 3 trial for APG777 in 2026.
• Anticipate commercial launch of APG777 this decade, subject to regulatory alignment.
• Expect readout from Phase 1b head-to-head trial of APG279 in the second half of 2026.
• Planned clinical trials for APG777 in asthma (Phase 2b initiation expected in 2025) and Eosinophilic Esophagitis (EoE) (Phase 2 initiation expected in 2026).
• Respiratory clinical planning underway for APG777 + APG333 combination.

Key Dates

Recommendation

Keywords

Atopic Dermatitis, AD, APG777, APG279, IL-13, OX40L, Clinical Trial, Phase 2, APEX, EASI, EASI-75, EASI-90, IGA, Itch NRS, Biologics, Dermatology, Biotechnology, Drug Development, Clinical-stage, Immunology, Inflammation, SEC Filing, 8-K